May
08
2026
Wake Up Narcolepsy 2026 National Summit Recap
The Wake Up Narcolepsy (WUN) 2026 National Summit took place on April 25th, at the...
13:15 /
News
May
04
2026
Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Narcolepsy
BOSTON, April 29, 2026 – The Institute for Clinical and Economic Review (ICER) today posted its revised Evidence...
08:22 /
News
Apr
17
2026
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
DUBLIN--(BUSINESS WIRE)--Apr. 16, 2026-- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the...
14:51 /
News
Apr
08
2026
2026 Narcolepsy Family Weekend Recap
Wake Up Narcolepsy (WUN)'s 2026 Family Weekend took place March 27th - 29th at the...
15:17 /
News
Apr
02
2026
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
DUBLIN--(BUSINESS WIRE)--Apr. 1, 2026-- Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a...
11:20 /
News
Apr
02
2026
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
INDIANAPOLIS and BOSTON and LONDON, March 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company...
08:38 /
News
Mar
30
2026
Join Us for April’s Brown Bag Webinar – Navigating Narcolepsy and Pregnancy
Join us on April 9th at 2pm ET for our next Brown Bag Webinar, “Navigating...
13:05 /
News
Feb
17
2026
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Feb. 17, 2026-- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug...
14:32 /
News
Feb
12
2026
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
DUBLIN--(BUSINESS WIRE)--Feb. 12, 2026-- Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes’...
11:51 /
News
Feb
10
2026
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
OSAKA, Japan and CAMBRIDGE, Massachusetts, February 10, 2026 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S....
10:32 /
News